{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:51:17Z","timestamp":1772826677237,"version":"3.50.1"},"reference-count":0,"publisher":"Frontline Medical Communications, Inc.","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.12788\/fp.0459","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T21:00:10Z","timestamp":1709845210000},"source":"Crossref","is-referenced-by-count":1,"title":["Clinical Implications of a Formulary Conversion From Budesonide\/formoterol to Fluticasone\/salmeterol at a VA Medical Center"],"prefix":"10.12788","volume":"41","author":[{"given":"Lindsay","family":"Hoke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5043","published-online":{"date-parts":[[2024,3,1]]},"container-title":["Federal Practitioner"],"original-title":[],"link":[{"URL":"https:\/\/cdn.mdedge.com\/files\/s3fs-public\/issues\/articles\/fdp04103080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T21:00:12Z","timestamp":1709845212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdedge.com\/fedprac\/article\/268067\/pulmonology\/clinical-implications-formulary-conversion-budesonide\/formoterol"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":0,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.12788\/fp.0459","relation":{},"subject":[],"published":{"date-parts":[[2024,3]]}}}